Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib


Sen F., Yildiz İ. , Başaran M., Ekenel M., Oz F., Kilic L., et al.

JOURNAL OF BUON, cilt.18, ss.775-781, 2013 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 18 Konu: 3
  • Basım Tarihi: 2013
  • Dergi Adı: JOURNAL OF BUON
  • Sayfa Sayısı: ss.775-781

Özet

Purpose: Hypertension is one of the major side effects of sunitinib, an angiogenesis inhibitor used in the treatment of metastatic renal cell carcinomas (mRCC) and gastrointestinal stromal tumors (GIST). Endothelial dysfunction, an early and reversible event in the pathogenesis of atherosclerosis, is suggested to be one of the possible underlying mechanisms of hypertension caused by angiogenesis inhibitors. Coronary flow reserve (CFR) measurement by trans-thoracic Doppler echocardiography (TTDE) reflects coronary microvascular and endothelial functions, as a cheaper and an easy screening test. We have used TTDE to evaluate endothelial function and coronary microvascular function in mRCC and GIST patients under sunitinib treatment.